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Dyspnoea is defined as ‘an uncomfortable sensation of breathing’
(Manning et al, 1995). It should be distinguished from respiratory
failure, which is defined as pulmonary dysfunction with hypoxia
and/or hypercapnoea. Published prevalence rates for dyspnoea in
cancer patients range from 29% to 74% in the terminal stage
(Reuben et al, 1986; Doyle et al, 1998). It is one of the most refrac-
tory symptoms (Higginson et al, 1989) in the terminal stage, even
when no tumour involvement is demonstrated in the lung (Bruera
et al, 1998). In spite of its high prevalence, limited research is
available on adequate assessment and management (Higginson
et al, 1989).
The pathophysiological mechanisms of dyspnoea are poorly
understood despite extensive research. Aetiology of dyspnoea can
not be always explained pathophysiologically. Some modulators,
such as psychological state, cultural background, environment and
life experiences, are recently considered to amplify or decrease the
intensity of the symptom perceived at the cortical level (Ripamonti
et al, 1997). Some studies have shown significant correlations
between dyspnoea and psychological status (Burns et al, 1969;
Dales et al, 1989; Gift et al, 1990; Moody et al, 1990; McCord
et al, 1992; O’Connor et al, 1996). Some other studies have shown
that the different terms describing dyspnoea are associated with
aetiology and various stimuli (Simon et al, 1989, 1990; Elliott
et al, 1991). These findings suggested that dyspnoea includes
several qualitatively distinct sensations that arise from different
mechanisms (Manning et al, 1995).
It is hypothesized that there might be several aspects of dysp-
noea; however, few studies about subtypes of dyspnoea in cancer
patients have been done and an appropriate assessment tool for
dyspnoea in this population has not been established. Available
scales are not appropriate for understanding the aetiologies and
establishing a therapeutic strategy for them. Some scales evalu-
ating the intensity of dyspnoea subjectively, such as Borg’s scale
(Borg, 1970) and the Visual Analog Scale of dyspnoea (Atkin,
1969), are simple and widely used, but multidimensional assess-
ment cannot be achieved with them. Some other scales, which
objectively measure physical effort evoking dyspnoea, such as
Hugh–Jones scale (Fletcher et al, 1959) and others (Medical
Research Council Committee, 1965; American Thoracic Society,
1978; McGavin et al, 1978), are not feasible for patients whose
activity is limited by other symptoms or disability. They are some-
times not useful because perceived dyspnoea has not always been
found to be correlated with the results of exercise tests and respira-
tory function tests (Burdon et al, 1983; Stoller et al, 1986; Maler
et al, 1987).
Development of a new measure is crucial to investigating the
aetiology and establishing a therapeutic strategy for dyspnoea
(Bruera et al, 1998). The scale should:
1. comprise multidimensional aspects
2. be self-rating, because dyspnoea is subjective
3. be easy and simple enough to be completed by patients
troubled by dyspnoea
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4. be evaluated not by physical effort evoking dyspnoea, but by
perceived dyspnoea itself so that even bedridden patients can
complete it
5. have its reliability and validity in cancer patients confirmed,
6. be sensitive to clinical changes due to treatment or progression
of the disease over time.
The purpose of this study was: (1) to develop a brief self-rating
scale to assess dyspnoea in cancer patients and (2) to validate it.
We paid particular attention to the multidimensionality of dysp-
noea, with the hypothesis that there might be psychological
aspects as well as physiological ones, as some reports have
suggested (Burns et al, 1969; Dales et al, 1989; Gift et al, 1990;
Moody et al, 1990; McCord et al, 1992; O’Connor et al, 1996).
METHODS
Subjects
Cancer patients at the National Cancer Center Hospital East,
Japan, participated. Eligible patients were required: (a) to have
been pathologically diagnosed as having cancer and to have been
informed of their diagnosis, (b) to be 18 years or older, (c) to be
well enough to complete the questionnaire, (d) to not be suffering
from severe mental or cognitive disorders. The study was
approved by the Institutional Review Board and the Ethics
Committee of the National Cancer Center. Written consent was
obtained after each patient had been fully informed of the purpose
of the study.
Study design
The study consisted of two phases: (1) a development phase (to
develop the dyspnoea scale) and (2) a validation phase (to confirm
its feasibility, reliability and validity).
Development phase
First, terms which describe, represent and evaluate dyspnoea were
collected in the following ways: (a) by interviewing dyspnoeic
cancer patients closely in a clinical setting, (b) by brainstorming
with medical experts (i.e. oncologists, psycho-oncologists and
nurses engaged in thoracic oncology and in palliative care unit for
more than 3 years) and (c) by picking up from reported papers on
dyspnoea. After collecting a huge pool of terms, the medical
experts made a majority decision after series of discussions to omit
the terms that may: (a) be difficult for anyone to understand, that
is, local dialect, jargon and vague vocabulary; (b) overlap each
other, that is, linguistically synonym; and (c) be confounded with
symptoms other than dyspnoea, for example, description of cough
and sputum. A preliminary questionnaire with 5-point scale,
ranging from 1 (not at all) to 5 (very much) was prepared.
Cancer patients were then asked to fill out this draft scale along
with the Visual Analogue Scale (VAS) of dyspnoea and modified
Borg’s scale. Inappropriate items that met the following criteria
were then eliminated from the draft scale: (a) items which quite a
few patients required further explanation to complete, (b) items
whose correlation with VAS of dyspnoea was not significant, and
(c) items whose standard deviation of response was less than 1.0.
These remaining items were then factor analysed by principal
component analysis with varimax rotation. The number of factors
were determined by the Scree test (Catell, 1978). Items that loaded
less than 0.65 were deleted from each subscale.
Translation of the scale into an English version was completed
by employing the standard ‘forward–backward’ translation proce-
dure (Bonomi et al, 1996), which consists of the following steps:
1. two professional native English translators performed
independent forward translations
2. a third, independent translator resolved discrepancies
3. the fourth, independent professional translator, a native
Japanese, back translated the reconciled version
4. three bilingual experts reviewed the revised version and
decided on the final version.
Validation phase
Additional eligibility criteria were applied in this phase, so that the
influence of confounding factors in a heterogeneous sample could
be avoided. Participants were diagnosed as having lung cancer in
an advanced stage (i.e. in clinical stage IIIa [unresectable], IIIb, or
IV) or recurrent stage. Consecutive outpatients and cross-sectional
inpatients in the Thoracic Oncology Division were asked to
complete the Cancer Dyspnoea Scale (CDS), after brief instruc-
tion. In addition to this scale, outpatients were requested to
complete other measures at home on the hospital-visit day and to
mail it by the following day. If there were any blanks, telephone
inquiry was made to obtain the missing answers, as agreed with
the participants. Participants were given a 500-yen prepaid tele-
phone-card for participating in the study.
Measures
Modified Borg’s scale
Modified Borg’s scale is a 12-point numerical plus verbal scale
that is easy to administer, is reproducible and has been found to
correlate with physiological parameters of lung disease in exercise
trials (Wolkove et al, 1989; Mador et al, 1995).
VAS of dyspnoea
VAS of dyspnoea is a 100-mm line anchored by the terms ‘no
dyspnoea’ and ‘worst possible dyspnoea’, on which intensity of
dyspnoea is marked. It has also been validated (Gift et al, 1989),
and is more sensitive and precise than Borg’s scale (Muza et al,
1990).
State-Trait Anxiety Inventory (STAI)
The STAI was used to investigate associations between anxiety
and the CDS. It consists of a 40-item self-rating questionnaire,
evaluating state- and trait-anxiety separately (Spielberger et al,
1970). The Japanese version has also been validated (Nakazato
et al, 1982).
Physician’s assessment, vital signs and laboratory data
Performance Status (PS) defined by the Eastern Cooperative
Oncology Group (ECOG) and the presence of pathophysiological
causes of dyspnoea was clinically evaluated on the same day by
physicians engaged in thoracic oncology for over 5 years. After
sitting at rest for 5 min, the patient’s oxygen saturation (SpO2) was
measured with a pulse oximeter at the digit.
Feasibility
Inpatients were observed to see whether they had any difficulty in
completing the CDS, and after they completed it they were asked802 K Tanaka et al
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directly if they had any difficulty in completing it. The time
required for inpatients to complete it was measured.
Validity
Construct validity (i.e. whether each subscale represents and
correlates with each dimension) was evaluated by factor analysis
followed by varimax rotation.
Intersubscale correlation (i.e. the strength of the correlations
between subscales) was evaluated by calculating Pearson’s corre-
lations.
Convergent validity (i.e. the strength of the correlations between
the subscale and aggregate, and other validated measures of
dyspnoea) was assessed by Pearson’s correlations with VAS 
of dyspnoea completed at the same time.
Reliability
Internal consistency (i.e. homogeneity) of the multiple item scales
was evaluated by calculating Cronbach’s alpha coefficient.
Test–retest reliability (i.e. reproducibility) was evaluated in a
group of consecutive outpatients who were asked to complete the
scale twice, about a week apart, and mail it each time. Patients
whose treatment, including all medications, was changed and/or
who experienced any noteworthy clinical event during that period
were excluded. The results on the two occasions were assessed by
Pearson’s correlation.
All statistical procedures were performed using SPSS 7.5.1J for
Windows (SPSS Inc., 1997).
RESULTS
Development phase
Interviews with about 20 dyspnoeic inpatients in the Thoracic
Oncology Division and Palliative Care Unit were held by the first
author. Brainstorming was repeated by 11 oncologists, six psycho-
oncologists and six nurses in the Thoracic Oncology Division and
Palliative Care Unit. With these procedures, 179 terms were listed;
most came from brainstorming and the remaining from interview
and checking reviews. These terms were reduced according to the
criteria described before. A preliminary questionnaire consisting
of 24 items was then prepared and delivered to 117 cancer patients.
There were more males (66.7%) than females, and the median age
was 61 years (range 36–80 years). The most frequent cancer site
was the lung (76.1%), followed by the breast (12.0%) and the
oesophagus (5.1%). Approximately half of patients’ cancers
(49.6%) were in the advanced stage (clinical stage III–IV) or in the
recurrent stage, and most of them (87.2%) had an ECOG PS of 0 
or 1.
Factor analysis was performed on the remaining items, after
discarding six inappropriate items according to the criteria previ-
ously defined. The number of factors was fixed at three, and six
items were deleted according to the criteria. The first factor,
accounting for 27% of the total variance, consisted of five items,
the second, accounting for 21%, contained four items, and the
third, accounting for 14%, consisted of three items. Cronbach’s
alpha coefficients for these factors were 0.87, 0.81 and 0.82,
respectively, which showed adequate internal consistency.
Pearson’s correlations between each factor were 0.27, 0.30 and
0.55, which meant that they were satisfactorily independent of
each other. Although it was difficult to interpret the meaning of
each factor on the basis of the wording of the questions alone, it
was hypothesized that these three factors indicate the following:
Factor 1, ‘sense of effort’, physical dyspnoea or dysfunction of
ventilation with organic cause(s) worsened on exertion; Factor 2,
‘sense of anxiety’, affected or amplified by psychological status;
Factor 3, ‘sense of discomfort’, unpleasant and unrelaxed feeling
at rest as well. Based on the results, a cancer dyspnoea scale
containing 12 items consisting of three factors was developed. The
maximum total score is 48: 20 points for ‘sense of effort’, 16 for
‘sense of anxiety’ and 12 for ‘sense of discomfort’; the higher the
score, the more severe the dyspnoea is (Appendix 2). An English
version of the scale has been completed (Appendix 1).
Validation phase
Subjects (Table 1)
Of the 139 outpatients and 31 inpatients who were asked to partic-
ipate, two refused (1%) because of lack of time or feeling too ill,
and two patients were excluded (1%) because of failure to reply.
The patients’ sociodemographic and clinical characteristics in this
phase are shown in Table 1.
Feasibility
All patients completed the Cancer Dyspnoea Scale easily without
assistance, but a few patients wavered in replying, because they
felt shortness of breath on exertion, but no dyspnoea at rest. Five
patients left one item unanswered, and three patients marked
Table 1 Demographic and clinical characteristics (n = 166)
Characteristics No. of patients (%)
Age (years) Median 64
Range 27–87
Sex Male 123 (74.1)
Married 147 (88.6)
Work outside the home 25 (16.1)
Education level (years)
–9 (junior high school or less) 90 (54.2)
10–12 (high school or less) 51 (30.7)
13– (beyond high school) 25 (15.1)
Outpatient 135 (81.3)
Histological type Adenocarcinoma 85 (51.2)
Small-cell 39 (23.5)
Squamous cell 38 (22.9)
Others 4 (2.4)
Clinical stage
No prior treatment IIIa 23 (13.9)
IIIb 56 (33.7)
IV 49 (29.5)
Recurrent case 38 (22.9)
Treatment Surgery 30 (18.1)
(multiple choice) Chemotherapy 129 (77.7)
Radiotherapy 69 (41.6)
Pleurodesis 8 (4.8)
PS (ECOG)* 0 31 (18.7)
1 125 (75.3)
2 4 (2.4)
3 4 (2.4)
4 2 (1.2)
Days after diagnosis Median 273
of cancer Range 14–3138
*Performance Status defined by Eastern Cooperative Oncology Group.double replies to an item (total eight patients; 4.8%). None of the
items clearly resulted in more errors than the others. The average
time required to complete the scale by the 31 inpatients was 140 s
(s.d. = 44.1, median = 138).
Validity
Construct validity (Table 2) Since the number of factors could
not be determined by the Scree test in this phase, we applied the
criteria (Kaiser et al, 1960) which limit factors whose eigenvalue is
greater than 1.0, according to the methodology of factor analysis
(Nunnally et al, 1994). The number was fixed at 3, the same as in
the development phase. Factor analysis reproduced the same
loading pattern.
Intersubscale correlation (Table 3)
There were significant correlations for all pairs of the subscale.
The mean value of the intersubscale correlation coefficient was
0.48.
Convergent validity (Table 4)
Each of the factors significantly correlated with VAS of dyspnoea
(average  r = 0.57, P < 0.001) and with modified Borg’s scale
(average r = 0.52, P < 0.001). Significant correlations were also
found between total score and PS, SpO2, STAI, and the presence of
pathophysiological cause(s).
Reliability (Table 5)
Internal consistency Cronbach’s alpha coefficients of the
subscale were 0.83, 0.81, and 0.94, respectively (average 0.86).
Test–retest reliability
All 37 patients completed the scale the first and second time an
average of 6.9 days apart (median = 7 days). Test–retest correla-
tion coefficients between each factor and the total score were 0.71,
0.69 and 0.58 respectively (P < 0.005).
Descriptive data (Table 5)
Table 5 shows the mean and standard deviations for each subscale
and the total score of the CDS.
DISCUSSION
The Cancer Dyspnoea Scale, a brief self-rating questionnaire
composed of 3 factors and 12 items, was developed and validated
in this study using the methodology established and utilized in
psychometry. To our knowledge, the CDS is the first scale that
evaluates the multidimensional nature of dyspnoea. It solved the
shortcomings of former assessment tools: (1) it comprises multidi-
mensional aspects, (2) it is self-rating, (3) it is easy and simple, (4)
it evaluates not physical effort evoking dyspnoea, but perceived
dyspnoea itself, and (5) it has confirmed its reliability and validity
in cancer patients.
The Cancer Dyspnoea Scale 803
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Table 2 Construct validity: factor loading pattern (followed by varimax
rotation) in the validation phase (n = 166)
Item number and content Factor 1a Factor 2b Factor 3c
10. Narrower 0.82 0.16 -0.25
12. Stuck in the airway 0.74 0.31 0.01
4. Short of breath 0.69 0.16 -0.27
8. Shallow 0.63 0.29 -0.26
6. Panting 0.61 0.35 -0.25
7. Breathing difficulty that one doesn’t
know what to do 0.11 0.85 -0.19
9. Breathing may stop 0.25 0.81 -0.15
5. Accompanied by palpitations and
sweating 0.38 0.67 0.01
11. As if drowning 0.45 0.65 -0.08
2. Exhale easily -0.16 -0.11 0.94
1. Inhale easily -0.29 -0.01 0.91
3. Breath slowly -0.18 -0.17 0.88
a‘Sense of effort’; b‘Sense of anxiety’; c‘Sense of discomfort’.
Table 3 Intersubscale correlation of Cancer Dyspnoea Scale factors
(n = 166)
Factor 1 Factor 2 Factor 3
Factor 1 – – –
Factor 2 0.65* – –
Factor 3 0.49* 0.31* –
Total score 0.91* 0.76a 0.75a
aP < 0.001
Table 4 Convergent validity: correlations between the Cancer Dyspnoea Scale and other measures
Physical status STAId Pathophysiologic
VASb of Borg’s cause(s)e
dyspnoea Scale PSc SpO2 State Trait P value
(n=166) (n=135) (n=135) (n=166)
Factor 1f 0.77a 0.72a 0.24a –0.20 0.22 0.26a <0.001
Factor 2g 0.53a 0.41a 0.18 –0.02 0.28a 0.33a 0.119
Factor 3h 0.40a 0.44a 0.13 –0.29a 0.09 0.22 <0.001
Total score 0.72a 0.67a 0.23a –0.23a 0.23a 0.32a <0.001
aP < 0.001. bVisual analogue scale; cperformance status defined by Eastern Cooperative Oncology Group; dState-Trait-Anxiety-Inventory; eevaluated by expert
physician; coded: 0, absent; 1, present; f‘Sense of effort’; g‘Sense of anxiety’; h‘Sense of discomfort’.
Table 5 Reliability and descriptive data of the Cancer Dyspnoea Scale
Reliability Descriptive data
Cronbach’s Test-retest
alpha reliability Mean (Fullscore) s.d.
coefficient (correlation
coefficient)
(n = 166) (n = 37) (n = 166)
Factor 1 0.83 0.71a 3.8 (20) 3.6
Factor 2 0.81 0.69a 1.1 (16) 2.1
Factor 3 0.94 0.58a 3.5 (12) 2.7
Total score 0.64 0.69a 8.3 (48) 6.9
aP < 0.001.804 K Tanaka et al
British Journal of Cancer (2000) 82(4), 800–805 © 2000 Cancer Research Campaign
The total- and sub-score of the CDS represent dyspnoea, which
was confirmed by a significant relation to VAS and modified
Borg’s scale. Each sub-score of the CDS represents the different
aspects of dyspnoea, which was revealed by examining the
relation to physical status (PS, SpO2) and psychological status
(measured by STAI). Factor 2 (referred to as ‘sense of anxiety’)
was significantly correlated with both state- and trait-anxiety, but
not with SpO2 or PS. These findings were interpreted as meaning
that Factor 2 reflects the psychological nature of dyspnoea ampli-
fied by anxiety rather than the patient’s physical condition. The
findings that this factor alone was unrelated to the presence of
organic causes strongly supported this interpretation. In contrast to
Factor 2, Factor 1 (referred to as ‘sense of effort’) was signifi-
cantly correlated with PS, which represents patients’ gross phys-
ical status. This was interpreted as meaning that Factor 1 reflects
the pathophysiological aspects of dyspnoea which are related to,
and perhaps precipitated by, physical activity. On the other hand,
Factor 3 (referred to as ‘sense of discomfort’) was significantly
correlated with SpO2 measured at rest. This was interpreted to
mean that Factor 3 reflects an uncomfortable feeling at rest rather
than shortness of breath on exertion. However, it still remains
difficult to name each factor fitly. The Pearson’s coefficiencies of
PS, SPO2 and STAI were not high, compared with that of VAS and
Borg’s scale. It might be explained that the scales used here for
convergent validity reflected only a certain part of characteristics
of dyspnoea. Further study, focusing on factors correlated with
each subscore of the CDS, is needed to better understand the char-
acter of each factor.
The lack of definite independence of each factor was observed
in the following findings. First, there were significant intercorrela-
tions between each factor (average 0.48). Second, some items
(such as item 11) loaded not for one, but for both of two factors.
Although factor analysis reproduced the same factor loading
pattern in the validations as in the development phase, construct
validity was not excellent. This suggested that the multiple dimen-
sions of dyspnoea overlap in such a complex manner and are
related to each other so closely that they cannot be clearly divided
into independent factors.
The CDS was confirmed to be acceptable and practicable in a
clinical setting. Simplicity and ease of completion even by dysp-
noeic patients is one of the most important features of the scale.
However, the time required to complete this scale (average: 140 s)
was longer than we expected. The difficulty of this scale, if any,
may lie in confusing patients, as to which condition they should
reply to, shortness of breath on exertion, or no dyspnoea at rest.
Symptoms, that vary over time, such as pain, should be evaluated
totally along with severity, frequency and distress (Reuben et al,
1986). Pain is, for example, often assessed at worst, at best and
over the last 24 h (Daut et al, 1982). However, since the design of
this scale strongly focused on brevity, it simply asked about
breathing difficulty during the past few days, so that any dyspnoea
perceived by the patient, regardless of occasion or cause, was
included. Contrary to our intention, this instruction may be some-
what vague and confusing to some patients.
The limitations of this study are: (1) the sensitivity of the scale
to clinical changes caused by treatment or progression of the
disease over time was not validated; (2) feasibility for patients
with poor PS, with severe dyspnoea was not confirmed; (3)
validity for patients other than lung cancer patients was not
confirmed; and (4) cross-cultural validation was also not
performed. Further improvements and validation are needed.
In conclusion, the CDS developed in this study is a brief, self-
rating scale that assesses the multidimensional nature of dyspnoea.
Its feasibility, reliability and validity are satisfactory for clinical
use, although a few problems still remain in its construction.
Further study of correlated factors on the CDS might contribute to
better understanding the aetiology of dyspnoea and establishing a
therapeutic strategy.
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APPENDIX 1
The Cancer Dyspnoea Scale
We would like to ask you about your breathlessness or difficulty in breathing. Please answer each question by circling only the numbers
that best describes the breathing difficulty that you felt during the past few days. Base your response on your first impression.
Not at all A little Somewhat Considerably Very much
1 Can you inhale easily? 1 2 3 4 5
2 Can you exhale easily? 1 2 3 4 5
3 Can you breathe slowly? 1 2 3 4 5
4 Do you feel short of breath? 1 2 3 4 5
5 Do you feel breathing difficultyaccompanied by palpitations and sweating? 1 2 3 4 5
6 Do you feel as if you are panting? 1 2 3 4 5
7 Do you feel such breathing difficulty that you don’t know what to do about it? 1 2 3 4 5
8 Do you feel your breath is shallow? 1 2 3 4 5
9 Do you feel your breathing may stop? 1 2 3 4 5
10 Do you feel your airway has become narrower? 1 2 3 4 5
11 Do you feel as if you are drowning? 1 2 3 4 5
12 Do you feel as if something is stuckin your airway? 1 2 3 4 5
APPENDIX 2
Calculation method
1. Add the scores for each factor together.
Factor 1 = (items 4 + 6 + 8 + 10 + 12) – 5 = sense of effort
Factor 2 = (items 5 + 7 + 9 + 11) – 4 = sense of anxiety
Factor 3 = 15 – (items 1 + 2 + 3) = sense of discomfort
2. Add the total scores for each factor together = total dyspnoea
*Subtractions are to make adjustments for 0 as a state of absence of dyspnoea.